Primary Biliary Cholangitis (PBC): A Patient's Complete Guide

Primary biliary cholangitis — formerly called primary biliary cirrhosis — is a chronic autoimmune liver disease in which your immune system slowly destroys the small bile ducts inside your liver. Without functioning bile ducts, bile backs up in the liver, causing inflammation, progressive scarring, and eventually cirrhosis if the disease isn't treated. The name change from "cirrhosis" to "cholangitis" happened in 2015 precisely because the old name terrified newly diagnosed patients — most of whom, with modern treatment, will never develop cirrhosis.

PBC predominantly affects women (9:1 female-to-male ratio) and is typically diagnosed between ages 40–60. It's not caused by anything you did. It's not contagious. It's not related to alcohol. It's your immune system targeting your bile ducts for reasons that remain poorly understood — and it's treatable, manageable, and, in most cases, compatible with a long and normal life.

What's happening inside your liver

Your liver contains thousands of tiny bile ducts — a branching network of tubes that collect bile (a digestive fluid produced by liver cells) and channel it toward the gallbladder and intestines. In PBC, your immune system produces autoantibodies — specifically anti-mitochondrial antibodies (AMA) — that attack the cells lining these small bile ducts, triggering chronic inflammation around the ducts (a pattern pathologists call "granulomatous cholangitis").

As the bile ducts are damaged and destroyed, bile flow becomes obstructed. Bile that should be draining into your intestines backs up into the liver tissue — a condition called cholestasis. Retained bile is toxic to liver cells. The chemical irritation from backed-up bile acids triggers further inflammation, activates fibrosis-producing cells (stellate cells), and over years to decades, can lead to progressive scarring and eventually cirrhosis.

The progression is typically very slow — measured in decades, not years. And with modern treatment (ursodeoxycholic acid, or UDCA), the progression can be dramatically slowed or halted entirely in most patients.

The symptoms: fatigue and itching dominate

PBC has a distinctive symptom profile that's very different from other liver diseases:

Fatigue: the #1 complaint

Up to 80% of PBC patients report significant fatigue — often as their most debilitating symptom. PBC fatigue is the same bone-deep, unrelenting exhaustion described in our liver fatigue guide: sleep doesn't fix it, rest doesn't relieve it, and it's completely out of proportion to activity. The fatigue of PBC doesn't correlate with disease severity — patients with early-stage PBC can have crippling fatigue while patients with advanced disease may not. This makes it particularly frustrating: your labs may look fine while you can barely get through the day.

The mechanism is poorly understood — theories include altered brain signaling from cholestasis, autonomic dysfunction, sleep architecture disruption, and central sensitization. Unfortunately, UDCA treatment (the primary therapy for PBC) does not reliably improve fatigue. This is one of the greatest unmet needs in PBC management.

Itching (pruritus): the signature symptom

Up to 70% of PBC patients develop pruritus — and for many, it's the symptom that leads to diagnosis. PBC itching has the characteristic features of cholestatic pruritus: no visible rash, worse at night, affecting palms, soles, and limbs, unresponsive to antihistamines, and worsened by warmth. It's caused by bile salts and other pruritogens (lysophosphatidic acid, autotaxin) accumulating in the skin when bile flow is impaired.

Read the full guide: Can Liver Disease Cause Itching?

Treatment options for PBC pruritus include cholestyramine (first-line bile acid binder), rifampin (second-line — effective but requires liver enzyme monitoring), naltrexone (opioid antagonist — third-line), sertraline (SSRI — fourth-line), and emerging IBAT inhibitors (odevixibat, maralixibat) showing promise in clinical trials.

Other symptoms

Dry eyes and dry mouth (sicca syndrome — associated autoimmune condition, present in up to 50% of PBC patients). Joint pain (non-destructive, rheumatoid-pattern). Xanthomas and xanthelasma (cholesterol deposits under the skin, particularly around the eyes — from impaired cholesterol metabolism). Bone disease (osteoporosis — PBC patients have the highest rates of bone loss among all liver diseases, due to impaired vitamin D absorption from bile flow obstruction). Hyperpigmentation (darkening of the skin, particularly in areas of chronic scratching).

How PBC is diagnosed

PBC has one of the most straightforward diagnostic pathways in hepatology — because of one highly specific blood test:

Anti-mitochondrial antibody (AMA): Present in approximately 95% of PBC patients. AMA is highly specific — it's found in PBC and almost nothing else. A positive AMA with elevated ALP (alkaline phosphatase) in the right clinical context is considered diagnostic of PBC without requiring a liver biopsy.

The diagnostic criteria (simplified) require two of the following three: elevated ALP for more than 6 months, positive AMA (titer ≥1:40), and liver biopsy showing characteristic bile duct lesions (granulomatous cholangitis).

In practice, most patients are diagnosed with AMA + elevated ALP — without needing a biopsy. Biopsy is reserved for AMA-negative cases (about 5% of PBC patients are AMA-negative but have other specific antibodies like anti-SP100 or anti-GP210) or cases with diagnostic uncertainty.

Additional lab findings that support PBC diagnosis: elevated GGT (gamma-glutamyl transferase, often rises alongside ALP), elevated IgM (immunoglobulin M — characteristically elevated in PBC, unlike AIH where IgG is elevated), and mildly elevated ALT and AST (much less dramatically than in autoimmune hepatitis).

Treatment: UDCA is the foundation

Ursodeoxycholic acid (UDCA / Ursodiol)

UDCA is the first-line treatment for PBC and has been the cornerstone of therapy since the 1990s. It's a naturally occurring bile acid that, when taken as medication, replaces the toxic bile acids backing up in your liver with a less toxic, more hydrophilic (water-friendly) form. This reduces bile acid-mediated liver cell damage, improves bile flow, slows or halts disease progression, and — in patients who respond well — significantly improves transplant-free survival.

Dose: 13–15 mg/kg/day, typically divided into 2–3 doses taken with meals (food improves absorption). For a 70 kg patient, that's approximately 900–1,050 mg daily.

Response: UDCA works — but not equally for everyone. Approximately 60–70% of patients have a "good response" (ALP drops to less than 1.5x the upper limit of normal, bilirubin normalizes, and/or a ≥40% decrease in ALP within 12 months). Patients with a good biochemical response have a transplant-free survival that approaches the general population. The remaining 30–40% have an inadequate response — and need additional therapy.

Obeticholic acid (OCA / Ocaliva) — second-line

For patients who don't respond adequately to UDCA alone, obeticholic acid (approved 2016) is added as second-line therapy. OCA is an FXR (farnesoid X receptor) agonist that reduces bile acid production and improves bile flow through a different mechanism than UDCA. Dose: started at 5 mg daily, increased to 10 mg if tolerated and needed. Side effect to watch: OCA can worsen itching (a significant limitation, since itching is already a major PBC complaint). It's contraindicated in decompensated cirrhosis.

Elafibranor (Iqirvo) — newest option

Elafibranor, a PPAR agonist, was approved in 2024 for PBC patients with inadequate response to UDCA. It improves ALP and bilirubin through a different pathway than both UDCA and OCA. Early data suggests it may have less pruritus worsening than OCA — a meaningful advantage given that itching is already one of PBC's most burdensome symptoms.

Seladelpar — in development

Another PPAR agonist in late-stage clinical trials, showing promising results for both biochemical improvement and pruritus reduction. The PBC treatment landscape is expanding rapidly — more options are coming.

Fibrates (bezafibrate, fenofibrate) — off-label

Used in some countries (particularly Japan and parts of Europe) as add-on therapy to UDCA. Evidence supports improvement in ALP and pruritus. Not FDA-approved for PBC in the US but may be prescribed off-label by some hepatologists.

Staging and prognosis

PBC progresses through histological stages (assessed by biopsy, though staging is increasingly done non-invasively):

The encouraging reality: with UDCA treatment, the majority of PBC patients diagnosed at Stages 1–2 never progress to cirrhosis. The median transplant-free survival for UDCA responders is comparable to the general population. PBC is no longer the progressive, inevitably fatal disease it was before UDCA — which is exactly why the name was changed from "cirrhosis" to "cholangitis" in 2015.

Non-invasive monitoring with FibroScan (liver stiffness measurement) is increasingly used to track fibrosis progression without repeated biopsies. Upload your lab reports to LiverTracker — ALP, GGT, bilirubin, albumin, and all other values are tracked on visual trend charts. The ALP trend in particular tells the story of how well your treatment is working.

Living with PBC: practical guidance

• Take UDCA with meals — food improves absorption significantly. Split into 2–3 doses across the day.

• Monitor bone health aggressively. PBC patients have the highest osteoporosis rates in liver disease. Get a baseline DEXA scan. Take vitamin D (often 2,000–4,000 IU/day) and calcium supplements. Exercise regularly. Discuss bisphosphonates if bone density declines.

• Manage dry eyes and dry mouth. Artificial tears, saliva substitutes, staying hydrated. If severe, your hepatologist may refer you to a rheumatologist for Sjögren's syndrome evaluation.

• Manage itching proactively. Don't suffer in silence. Escalate through treatment options (cholestyramine → rifampin → naltrexone → sertraline) until you find what works. Itching is treatable — it just requires persistence.

• Screen for associated autoimmune conditions. Thyroid function (TSH, free T4) should be checked at diagnosis and periodically. Celiac screening may be appropriate. Report any new joint, skin, or digestive symptoms that might indicate another autoimmune condition developing.

• Avoid cholestyramine within 4 hours of other medications — it binds drugs in the gut and reduces their absorption. Take it separately from UDCA and all other medications.

Frequently asked questions

Is PBC the same as PSC?

No. PBC (primary biliary cholangitis) targets the small bile ducts inside the liver and predominantly affects women. PSC (primary sclerosing cholangitis) targets the large bile ducts (both inside and outside the liver), predominantly affects men, and is strongly associated with inflammatory bowel disease (ulcerative colitis). Both are autoimmune, both are cholestatic, but they're distinct diseases with different treatments and prognoses.

Will UDCA cure PBC?

UDCA controls PBC — it doesn't cure it. You'll take it for life. In patients who respond well (60–70%), UDCA slows or halts disease progression and provides near-normal life expectancy. But stopping UDCA allows the disease to reactivate. Think of it like blood pressure medication — it controls the condition as long as you take it.

Can PBC cause liver cancer?

PBC patients who progress to cirrhosis have an increased risk of hepatocellular carcinoma (HCC) — similar to cirrhosis from any other cause. HCC screening (AFP + ultrasound every 6 months) is recommended for all PBC patients with cirrhosis. PBC patients without cirrhosis are not at meaningfully elevated HCC risk and don't require screening.

Is PBC hereditary?

PBC isn't directly inherited in a simple Mendelian pattern, but there is a genetic predisposition. First-degree relatives (siblings, children) of PBC patients have a higher risk of developing PBC than the general population — estimated at 4–6% for siblings. Environmental triggers on top of genetic susceptibility are believed to drive the disease. If you have PBC, informing family members so they can be screened (AMA and ALP) if symptoms develop is reasonable — but routine screening of asymptomatic family members isn't standard practice.

Why did the name change from "primary biliary cirrhosis"?

Because the old name was inaccurate and harmful. Most PBC patients diagnosed and treated today never develop cirrhosis — the name implied a prognosis that no longer applies. Patients were terrified by a label that didn't match their reality. The international hepatology community officially changed the name to "primary biliary cholangitis" in 2015 — keeping the same abbreviation (PBC) while removing the stigma and inaccuracy of "cirrhosis" from a disease that, with treatment, usually doesn't progress to it.

PBC is an autoimmune disease with a treatment that works. Take your UDCA. Track your ALP. Manage your symptoms. And know that the vast majority of treated PBC patients live long, full lives — the "cirrhosis" in the old name was the exception, not the rule.

→ Check Your Liver Enzymes Free

→ Start Tracking Free

→ Calculate Your MELD Score

Medical Disclaimer: This article is for informational and educational purposes only. PBC management should be directed by a hepatologist experienced in autoimmune liver disease. Never change UDCA doses without medical guidance. Visit livertracker.com/medical-disclaimer.